Clinical trial
Denileukin Diftitox in Treating Patients With Relapsed or Refractory…
NCT00138164 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00138164 |
|---|---|
| Title | Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase II Multicenter Study of Ontak® (Denileukin Diftitox) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | denileukin diftitox |
| Enrollment | 50 |
| Start date | Dec 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Nov 1, 2008 |
| First posted | Aug 30, 2005 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: